

09567863

CLMN Number of Claims: 29  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 18716

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the compositions, methods, and applications of a novel approach to selective cellular targeting. The purpose of this invention is to enable the selective delivery and/or selective activation of effector molecules to target cells for diagnostic or therapeutic purposes. The present invention relates to multi-functional prodrugs or targeting vehicles wherein each functionality is capable of enhancing targeting selectivity, affinity, intracellular transport, activation or detoxification. The present invention also relates to ultra-low dose, multiple target, multiple drug chemotherapy and targeted immunotherapy for cancer treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 28 USPATFULL on STN  
AN 2003:194178 USPATFULL  
TI Immunomodulatory compositions, formulations, and methods for use thereof  
IN Fearon, Karen L., Lafayette, CA, UNITED STATES  
Dina, Dino, Oakland, CA, UNITED STATES  
PI US 2003133988 A1 20030717  
AI US 2002-214799 A1 20020807 (10)  
PRAI US 2001-310743P 20010807 (60)  
US 2001-335263P 20011025 (60)  
DT Utility  
FS APPLICATION  
LREP Nicholas S. Buffinger, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA, 94304-1018  
CLMN Number of Claims: 63  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3014

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMO/MC) complexes comprising 3-6 mer immunomodulatory oligonucleotides. The IMO/MC complexes may be covalently or non-covalently bound. Also provided are immunomodulatory compositions comprising a 3-6 mer IMO encapsulated in an MC.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 28 USPATFULL on STN  
AN 2003:187464 USPATFULL  
TI Biodegradable immunomodulatory formulations and methods for use thereof  
IN Van Nest, Gary, Martinez, CA, UNITED STATES  
Tuck, Stephen, Oakland, CA, UNITED STATES  
PI US 2003129251 A1 20030710  
AI US 2001-802359 A1 20010309 (9)  
PRAI US 2000-188303P 20000310 (60)  
DT Utility  
FS APPLICATION  
LREP MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018  
CLMN Number of Claims: 71  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2569

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



09567863

AB The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a biodegradable microcarrier or nanocarrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 28 USPATFULL on STN  
AN 2003:146381 USPATFULL  
TI Fusion protein arrays on metal substrates for surface plasmon resonance imaging  
IN Corn, Robert M., Madison, WI, UNITED STATES  
Smith, Emily A., Madison, WI, UNITED STATES  
Weisblum, Bernard, Madison, WI, UNITED STATES  
Erickson, Matthew G., Madison, WI, UNITED STATES  
Ulijasz, Andrew T., Madison, WI, UNITED STATES  
Wanat, Matthew J., Madison, WI, UNITED STATES  
PI US 2003100127 A1 20030529  
AI US 2002-99424 A1 20020315 (10)  
PRAI US 2002-362178P 20020306 (60)  
US 2001-304246P 20010710 (60)  
DT Utility  
FS APPLICATION  
LREP DEWITT ROSS & STEVENS S.C., 8000 EXCELSIOR DR, SUITE 401, MADISON, WI, 53717-1914  
CLMN Number of Claims: 78  
ECL Exemplary Claim: 1  
DRWN 8 Drawing Page(s)  
LN.CNT 1886

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are methods for making surface plasmon resonance-capable arrays wherein molecules, such as proteins or nucleic acids, or cells, are adhered to a metal substrate. The metal substrates are modified by depositing an  $\omega$ -modified alkanethiol monolayer to the substrate and then contacting the  $\omega$ -modified monolayer with a heterobifunctional linking compound. Biomolecules or cells can then be attached to the heterobifunctional linking compound. Also disclosed are arrays wherein glutathione-containing molecules are immobilized on the substrate and GST-containing molecules are then specifically immobilized onto the substrate, taking advantage of the affinity between glutathione and GST.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 28 USPATFULL on STN  
AN 2003:86168 USPATFULL  
TI Immunomodulatory formulations and methods for use thereof  
IN Van Nest, Gary, Martinez, CA, UNITED STATES  
Tuck, Stephen, Oakland, CA, UNITED STATES  
Fearon, Karen L., Lafayette, CA, UNITED STATES  
Dina, Dino, Oakland, CA, UNITED STATES  
PI US 2003059773 A1 20030327  
AI US 2001-927884 A1 20010810 (9)  
RLI Continuation-in-part of Ser. No. US 2001-802376, filed on 9 Mar 2001, PENDING  
PRAI US 2000-188557P 20000310 (60)  
DT Utility  
FS APPLICATION  
LREP Karen R. Zachow, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA, 94304-1018



09567863

CLMN Number of Claims: 79  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2969

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a nonbiodegradable microcarrier or nanocarrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 28 USPATFULL on STN  
AN 2003:70981 USPATFULL  
TI Immunomodulatory polynucleotides and methods of using the same  
IN Fearon, Karen L., Lafayette, CA, UNITED STATES  
Dina, Dino, Oakland, CA, UNITED STATES  
PI US 2003049266 A1 20030313  
AI US 2001-33243 A1 20011227 (10)  
PRAI US 2000-258675P 20001227 (60)  
DT Utility  
FS APPLICATION  
LREP Karen R. Zachow, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA, 94304-1018  
CLMN Number of Claims: 48  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3623

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 28 USPATFULL on STN  
AN 2003:30903 USPATFULL  
TI Biodegradable immunomodulatory formulations and methods for use thereof  
IN Nest, Gary Van, Martinez, CA, UNITED STATES  
Tuck, Stephen, Oakland, CA, UNITED STATES  
Fearon, Karen L., Lafayette, CA, UNITED STATES  
Dina, Dino, Oakland, CA, UNITED STATES  
PI US 2003022852 A1 20030130  
AI US 2001-927422 A1 20010810 (9)  
RLI Continuation-in-part of Ser. No. US 2001-802359, filed on 9 Mar 2001, PENDING  
PRAI US 2000-188303P 20000310 (60)  
DT Utility  
FS APPLICATION  
LREP MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018  
CLMN Number of Claims: 84  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3417

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence



09567863

bound to a biodegradable microcarrier or noncarrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 28 USPATFULL on STM  
AN 2003:155672 USPATFULL  
TI Method for the treatment of cystic fibrosis  
IN Macias, William Louis, Indianapolis, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 6576654 B1 20030610  
WO 9916453 19990408  
AI US 2000-508209 20000308 (9)  
WO 1998-US19906 19980923  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Weddington, Kevin E.  
LREP Benjamin, Roger S.  
CLMN Number of Claims: 1  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN CNT 2942

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is disclosed for the treatment of cystic fibrosis by administering to a human in need thereof a therapeutically effective amount of an SPLA.sub.2 inhibitor, such as a 1H-indole-3-glyoxylamide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 28 USPATFULL on STM  
AN 2002:307840 USPATFULL  
TI DNA-bridged carbon nanotube arrays  
IN Kelley, Shana O., Boston, MA, UNITED STATES  
Fourkas, John, Chestnut Hill, MA, UNITED STATES  
Naughton, Michael, Norwood, MA, UNITED STATES  
Ren, Zhifeng, Newton, MA, UNITED STATES  
PI US 2002172963 A1 20021121  
AI US 2002-42911 A1 20020109 (10)  
PRAI US 2001-260758P 20010110 (60)  
DT Utility  
FS APPLICATION  
LREP PALMER & DODGE, LLP, PAULA CAMPBELL EVANS, 111 HUNTINGTON AVENUE,  
BOSTON, MA, 02199  
CLMN Number of Claims: 59  
ECL Exemplary Claim: 1  
DRWN 16 Drawing Page(s)  
LN CNT 1170

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A class of biological sensing devices that include a substrate comprising an array of carbon nanotubes (CNTs) to which are chemically attached biological molecules is disclosed. The attached biological molecules are capable of electrical conductivity that is responsive to chemical changes occurring as a result of their interaction with target species. A means for means for using DNA as a material of potential in molecular electronic sensor devices, being primarily based on molecular electron-transfer reaction processes between DNA-binding donors and acceptors is also disclosed, including composition, method of manufacture and their use are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 28 USPATFULL on STM



09567863

AN 2002:164713 USPATFULL  
TI Crystal structure of worm NitFhit reveals that a Nit tetramer binds two  
Fhit dimers  
IN Croce, Carlo, Philadelphia, PA, UNITED STATES  
Brenner, Charles, Philadelphia, PA, UNITED STATES  
Pekarsky, Yuri, Philadelphia, PA, UNITED STATES  
PI US 2002086331 A1 20020704  
AI US 2001-855294 A1 20010515 (9)  
PRAI US 2000-204713P 20000516 (60)  
DT Utility  
FS APPLICATION  
LREP THOMAS JEFFERSON UNIVERSITY, 1020 Walnut Street - Suite 630,  
Philadelphia, PA, 19107-5587  
CLMN Number of Claims: 40  
ECL Exemplary Claim: 1  
DRWN 6 Drawing Page(s)  
LN.CNT 2059

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In invertebrates, Fhit is encoded as a fusion protein with Nit. Outside  
of invertebrates, Nit homologs are found as separate polypeptides in  
organisms with Fhit homologs. Therefore, Nit and Fhit are expected to  
interact physically and function in the same cellular pathway. The  
structure of the NitFhit fusion protein and interactions between the Nit  
and Fhit polypeptides are defined. The present invention relates to the  
identification of small molecules that interact with, and regulate, the  
Nit protein. The present invention further relates to therapeutic  
compositions and their uses in regulating Nit activity, thereby  
modulating cellular proliferation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 28 USPATFULL on STN  
AN 2002:106268 USPATFULL  
TI Immunomodulatory formulations and methods for use thereof  
IN Nest, Gary Van, Martinez, CA, UNITED STATES  
Tuck, Stephen, Oakland, CA, UNITED STATES  
PI US 2002055477 A1 20020509  
AI US 2001-802376 A1 20010309 (9)  
PRAI US 2000-188557P 20000310 (60)  
DT Utility  
FS APPLICATION  
LREP Karen R. Zachow, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto,  
CA, 94304-1018  
CLMN Number of Claims: 66  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2435

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides new compositions and methods for immunomodulation  
of individuals. Immunomodulation is accomplished by administration of  
immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The  
IMP/MC complexes may be covalently or non-covalently bound, and feature  
a polynucleotide comprising at least one immunostimulatory sequence  
bound to a nonbiodegradable microcarrier or nanocarrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 28 USPATFULL on STN  
AN 2002:254185 USPATFULL  
TI Methods for determining single nucleotide variations and  
genotyping  
IN Miller, Andrew P., San Diego, CA, United States



09567863

PA DNA Sciences, Inc., Fremont, CA, United States (U.S. corporation)  
PI US 6458544 B1 20021001  
AI US 2000-728451 20001201 (9)  
PRAI US 1999-168580P 19991202 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Horlick, Kenneth R.; Assistant Examiner: Strzelecka, Teresa  
LREP Townsend and Townsend and Crew LLP  
CLMN Number of Claims: 39  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)  
LN.CNT 1354

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods and kits for determining the identity of a nucleotide at a variant site on a target nucleic acid. The methods begin with the template-dependent amplification of a target sequence under defined conditions to achieve selective incorporation of a nucleotide analog at the variant site. Amplification product is then subjected to limited degradation to create products having allele-specific sizes, which are subsequently separated on the basis of size. Finally, the number of products and their sizes is to assessed to determine the identity of the nucleotide(s) at the variant site and the genotype of the organism from which the target was obtained.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 28 USPATFULL on STN  
AN 2001:176372 USPATFULL  
TI Method and apparatus for combinatorial chemistry  
IN Foote, Robert S., Oak Ridge, TN, United States  
PI US 2001029028 A1 20011011  
AI US 2001-859028 A1 20010516 (9)  
RLI Continuation of Ser. No. US 1999-305591, filed on 5 May 1999, PENDING  
DT Utility  
FS APPLICATION  
LREP LUEDEKA NEELY & GRAHAM, P.C., P O BOX 1871, KNOXVILLE, TN, 37901-1871  
CLMN Number of Claims: 47  
ECL Exemplary Claim: 1  
DRWN 6 Drawing Page(s)  
LN.CNT 1150

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method and apparatus are provided for performing light-directed reactions in spatially addressable channels within a plurality of channels. One aspect of the invention employs photoactivatable reagents in solutions disposed into spatially addressable flow streams to control the parallel synthesis of molecules immobilized within the channels. The reagents may be photoactivated within a subset of channels at the site of immobilized substrate molecules or at a light-addressable site upstream from the substrate molecules. The method and apparatus of the invention find particularly utility in the synthesis of biopolymer arrays, e.g., oligonucleotides, peptides and carbohydrates, and in the combinatorial synthesis of small molecule arrays for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 28 USPATFULL on STN  
AN 2001:190907 USPATFULL  
TI Length determination of nucleic acid repeat sequences by discontinuous primer extension  
IN Livak, Kenneth J., San Jose, CA, United States



09567863

Lowe, Adam L., San Francisco, CA, United States  
Blasband, Andrew J., Redwood City, CA, United States  
PA PE Corporation (NY), Foster City, CA, United States (U.S. corporation)  
PI US 6309829 B1 20011030  
AI US 1998-205114 19981203 (9)  
RLI Continuation-in-part of Ser. No. US 1997-863437, filed on 27 May 1997,  
now patented, Pat. No. US 5945284  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Campbell, Eggerton A.; Assistant Examiner: Chunduru,  
Suryaprabha  
LREP Powers, Vincent M., Grossman, Paul D.  
CLMN Number of Claims: 32  
ECL Exemplary Claim: 1  
DRWN 8 Drawing Figure(s); 7 Drawing Page(s)  
LN.CNT 1560

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a method for determining the number of repeat units in a repeat region of a target nucleic acid. In a first aspect, the method of the invention includes the steps of annealing a primer to a target nucleic acid; performing a first primer extension reaction using a first primer extension reagent; separating the target-primer hybrid and unreacted first primer extension reagent; performing a second primer extension reaction using a second primer extension reagent, wherein at least one of the first or second primer extension reagents includes an extendible nucleotide having a label attached thereto; separating the target-primer hybrid from unreacted second primer extension reagent; measuring a signal produced by the label; treating the label so as to render the label undetectable; and repeating the above steps until the signal is substantially less than a signal detected in a previous cycle. In a second aspect, the method of the invention includes the steps of annealing a primer to a target nucleic acid; performing a first primer extension reaction using a first primer-extension reagent; separating the target-primer hybrid from unreacted first primer extension reagent; performing a second primer extension reaction using a second primer extension reagent and with a primer termination reagent, the primer termination reagent including a nucleotide terminator having a label attached thereto; separating the target-primer hybrid from unreacted second primer extension reagent and unreacted primer termination reagent; measuring a signal produced by the label; and repeating the above steps until a signal is detected indicating incorporation of the nucleotide terminator. The invention further includes kits useful for practicing the above methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 20 OF 28 USPATFULL on STN  
AN 2001:117163 USPATFULL  
TI Thiol-derivatized nucleosides and oligonucleosides  
IN Cook, Phillip Dan, Fallbrook, CA, United States  
Manoharan, Muthiah, Carlsbad, CA, United States  
PA ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)  
PI US 6265558 B1 20010724  
AI US 1999-383856 19990826 (9)  
RLI Continuation of Ser. No. US 1997-924326, filed on 5 Sep 1997, now patented, Pat. No. US 6114513 Continuation of Ser. No. US 1995-458396, filed on 2 Jun 1995, now patented, Pat. No. US 5852182  
Continuation-in-part of Ser. No. US 1993-116801, filed on 3 Sep 1993  
Continuation-in-part of Ser. No. US 211882, now patented, Pat. No. US 5578718, said Ser. No. US 116801 And Ser. No. US 1999-383856, filed on



09567863

26 Aug 1999 Continuation-in-part of Ser. No. US 1991-782374, filed on 24 Oct 1991, now abandoned Continuation-in-part of Ser. No. US 1990-463358, filed on 11 Jan 1990, now abandoned Continuation-in-part of Ser. No. US 1990-566977, filed on 13 Aug 1990, now abandoned

DT Utility  
PS GRANTED  
EXNAM Primary Examiner: Wilson, James O.  
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP  
CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1640

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nucleosides and linked nucleosides functionalized to include alkylthiol chemical functionality at ribofuranosyl positions, nucleosidic base positions, or on internucleoside linkages. In certain embodiments, the compounds of the invention further include steroids, reporter molecules, reporter enzymes, lipophilic molecules, peptides or proteins attached to the nucleosides through the alkylthio group.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 21 OF 28 USPATFULL on STN  
AN 2000:117894 USPATFULL  
TI Thiol-derivatized oligonucleotides  
IN Cook, Phillip Dan, San Marcos, CA, United States  
Manoharan, Muthiah, Carlsbad, CA, United States  
PA Isis Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)  
PI US 6114513 20000905  
AI US 1997-924326 19970905 (8)  
RLI Continuation of Ser. No. US 1995-458396, filed on 2 Jun 1995, now patented, Pat. No. US 5852182 which is a continuation-in-part of Ser. No. US 116801 which is a continuation-in-part of Ser. No. WO 1992-US9196, filed on 23 Oct 1992, now patented, Pat. No. WO 5578718 which is a continuation-in-part of Ser. No. US 1991-782374, filed on 24 Oct 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-463358, filed on 11 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-566977, filed on 13 Aug 1990, now abandoned

DT Utility  
PS Granted  
EXNAM Primary Examiner: Wilson, James O.  
LREP Woodcock Washburn Kurtz MacKiewicz & Norris LLP  
CLMN Number of Claims: 27  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1728

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nucleosides and linked nucleosides functionalized to include alkylthiol chemical functionality at ribofuranosyl positions, nucleosidic base positions, or on internucleoside linkages. In certain embodiments, the compounds of the invention further include steroids, reporter molecules, reporter enzymes, lipophilic molecules, peptides or proteins attached to the nucleosides through the alkylthio group.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 28 USPATFULL on STN  
AN 2000:109545 USPATFULL  
TI Assays using base protected table 1  
IN Hanna, Michelle M., Norman, OK, United States



09567863

PA The Board of Regents of the University of Oklahoma, United States (U.S. corporation)  
PI US 6107039 20000822  
AI US 1998-165451 19981002 (9)  
RLI Continuation of Ser. No. US 1997-899022, filed on 23 Jul 1997, now patented, Pat. No. US 6008334  
PRAI US 1996-22573P 19960724 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Marschel, Ardin H.  
LREP Dunlap, Coddling & Rogers, PC.  
CLMN Number of Claims: 38  
ECL Exemplary Claim: 1  
DRWN 9 Drawing Figure(s); 6 Drawing Page(s)  
LN.CNT 2325

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to protected thiol analogs of pyrimidine bases for syntheses of DNA and RNA by chemical or enzymatic methods. The subject analogs include reagents suitable for DNA or RNA synthesis via phosphoramidite, H-phosphonate or phosphotriester chemistry as well as reagents suitable for use by RNA and DNA polymerase, including thermostable polymerases employed by PCR or other nucleic acid amplification techniques. The nucleotide analogs synthesized by methods of this invention can thus be incorporated into oligonucleotides or polynucleotides, deprotected and derivatized with a functional group. In some cases the protecting groups are themselves antigenic and may be left on the oligonucleotides or polynucleotides for detection with antibodies. A method of synthesizing oligonucleotides with a functional group using the subject nucleotide analogs is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 23 OF 28 USPATFULL on STN  
AN 1999-170726 USPATPULL  
TI Base-protected nucleotide analogs with protected thiol groups  
IN Hanna, Michelle M., Norman, OK, United States  
PA The Board of Regents of the University of Oklahoma, Norman, OK, United States (U.S. corporation)  
PI US 6008334 19991228  
AI US 1997-899022 19970723 (8)  
PRAI US 1996-22573P 19960724 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Marschel, Ardin H.  
LREP Dunlap & Coddling, P.C.  
CLMN Number of Claims: 37  
ECL Exemplary Claim: 1  
DRWN 9 Drawing Figure(s); 6 Drawing Page(s)  
LN.CNT 2322

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to protected thiol analogs of pyrimidine bases for syntheses of DNA and RNA by chemical or enzymatic methods. The subject analogs include reagents suitable for DNA or RNA synthesis via phosphoramidite, H-phosphonate or phosphotriester chemistry as well as reagents suitable for use by RNA and DNA polymerase, including thermostable polymerases employed by PCR or other nucleic acid amplification techniques. The nucleotide analogs synthesized by methods of this invention can thus be incorporated into oligonucleotides or polynucleotides, deprotected and derivatized with a functional group. In some cases the protecting groups are themselves antigenic and may be left on the oligonucleotides or



09567863

polynucleotides for detection with antibodies. A method of synthesizing oligonucleotides with a functional group using the subject nucleotide analogs is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 24 OF 28 USPATFULL on STN  
AN 1999:102675 USPATFULL  
TI Electrochemical-based molecular detection apparatus and method  
IN Krihak, Michael, Phoenix, AZ, United States  
Shieh, Chan-Long, Paradise Valley, AZ, United States  
PA Motorola, Inc., Schaumburg, IL, United States (U.S. corporation)  
PI US 5945286 19990831  
AI US 1997-956676 19971023 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Marschel, Ardin H.  
LREP Parsons, Eugene A., Koch, William E.  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Figure(s); 1 Drawing Page(s)  
LN CNT 304

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A molecular detection apparatus including an electrode, a peptide nucleic acid probe covalently bonded to the electrode and a protective layer covering portions of the electrode not having attached probes which prevents oxidation/reduction of intercalator molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 25 OF 28 USPATFULL on STN  
AN 1999:102673 USPATFULL  
TI Length determination of nucleic acid repeat sequences by discontinuous primer extension  
IN Livak, Kenneth J., San Jose, CA, United States  
Lowe, Adam L., San Francisco, CA, United States  
Blasband, Andrew J., Redwood City, CA, United States  
PA The Perkin-Elmer Corporation, Foster City, CA, United States (U.S. corporation)  
PI US 5945284 19990831  
AI US 1997-863437 19970527 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Whisenant, Ethan  
LREP Grossman, Paul D.  
CLMN Number of Claims: 15  
ECL Exemplary Claim: 1  
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)  
LN CNT 903

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In a first aspect, the method of the invention includes the steps of annealing a primer to a target nucleic acid; performing a first primer extension reaction using a first primer extension reagent; separating the target-primer hybrid and unreacted first primer extension reagent; performing a second primer extension reaction using a second primer extension reagent, wherein at least one of the first or second primer extension reagents includes an extendible nucleotide having a label attached thereto; separating the target-primer hybrid from unreacted second primer extension reagent; measuring a signal produced by the label; treating the label so as to render the label undetectable; and repeating the above steps until the signal is substantially less than a signal detected in a previous cycle. In a second aspect, the



09567863

method of the invention includes the steps of annealing a primer to a target nucleic acid; performing a first primer extension reaction using a first primer-extension reagent; separating the target-primer hybrid from unreacted first primer extension reagent; performing a second primer extension reaction using a second primer extension reagent and with a primer termination reagent, the primer termination reagent including a nucleotide terminator having a label attached thereto; separating the target-primer hybrid from unreacted second primer extension reagent and unreacted primer termination reagent; measuring a signal produced by the label; and repeating the above steps until a signal is detected indicating incorporation of the nucleotide terminator. The invention further includes kits useful for practicing the above methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 26 OF 28 USPATFULL on STN  
AN 1998:160111 USPATFULL  
TI Thiol-derivatized oligonucleosides  
IN Cook, Phillip Dan, San Marcos, CA, United States  
Manoharan, Muthiah, Carlsbad, CA, United States  
PA ISIS Pharmaceuticals Inc., Carlsbad, CA, United States (U.S. corporation)  
PI US 5852182 19981222  
AI US 1995-458396 19950602 (8)  
RLI Continuation-in-part of Ser. No. US 1993-116801, filed on 3 Sep 1993, now patented, Pat. No. US 5578718 which is a continuation-in-part of Ser. No. US 1991-782374, filed on 24 Oct 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-463358, filed on 11 Jan 1990, now abandoned And a continuation-in-part of Ser. No. US 1990-566977, filed on 13 Aug 1990, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Wilson, James O.  
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1509

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nucleosides and linked nucleosides functionalized to include alkylthiol chemical functionality at ribofuranosyl positions, nucleosidic base positions, or on internucleoside linkages. In certain embodiments, the compounds of the invention further include steroids, reporter molecules, reporter enzymes, lipophilic molecules, peptides or proteins attached to the nucleosides through the alkylthio group.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 27 OF 28 USPATFULL on STN  
AN 96:109084 USPATFULL  
TI Thiol-derivatized nucleosides  
IN Cook, Phillip D., Carlsbad, CA, United States  
Manoharan, Muthiah, Carlsbad, CA, United States  
PA ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)  
PI US 5578718 19961126  
AI US 1993-116801 19930903 (8)  
RLI Continuation-in-part of Ser. No. US 1994-211882, filed on 22 Apr 1994 which is a continuation-in-part of Ser. No. US 1991-782374, filed on 24 Oct 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-463358, filed on 11 Jan 1990, now abandoned And Ser. No. US



09567863

1990-566977, filed on 13 Aug 1990, now abandoned

DT Utility  
FS Granted  
EXNAM Primary Examiner: Wilson, James O.  
LREP Woodcock Washburn Kurtz Mackiewicz & Norris  
CLMN Number of Claims: 25  
ECL Exemplary Claim: 1,24  
DRWN No Drawings  
LN.CNT 1330

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nucleosides and linked nucleosides functionalized to include alkylthiol chemical functionality at ribofuranosyl positions, nucleosidic base positions, or on internucleoside linkages. In certain embodiments, the compounds of the invention further include steroids, reporter molecules, reporter enzymes, lipophilic molecules, peptides or proteins attached to the nucleosides through the alkylthio group.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 28 OF 28 USPATFULL on STN  
AN 96:77631 USPATFULL  
TI Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof  
IN Holmes, Christopher P., Sunnyvale, CA, United States  
PA AFFYMAX Technologies NV, Curacao, Netherlands Antilles (non-U.S. corporation)

PI US 5549974 19960827  
AI US 1994-265090 19940623 (8)

DT Utility  
FS Granted

EXNAM Primary Examiner: Datlow, Philip I.; Assistant Examiner: Wong, King Lit  
LREP Stevens, Lauren L.  
CLMN Number of Claims: 11  
ECL Exemplary Claim: 1  
DRWN 28 Drawing Figure(s); 18 Drawing Page(s)  
LN.CNT 2054

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides an efficient and versatile method for the combinatorial synthesis and screening of libraries of 4-thiazolidinones, metathiazanones, and derivatives thereof. In order to expediently synthesize a combinatorial library of derivatives based upon these core structures, a general methodology for the solid phase synthesis of these derivatives is also provided. Arrays of thiazolidinones, metathiazanones, and derivatives thereof useful as peptidomimetics and for the identification of agents having antifungal, antihistaminic, or antimicrobial activity or use in the treatment of inflammation, hypertension, renal failure, congestive heart failure, uremia and other conditions can be prepared using this method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



10/070,728

FILE 'HOME' ENTERED AT 10:43:09 ON 27 MAR 2004

=> file biosis medline caplus wpids uspatfull  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.63	0.63

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 10:44:46 ON 27 MAR 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'MEDLINE' ENTERED AT 10:44:46 ON 27 MAR 2004

FILE 'CAPLUS' ENTERED AT 10:44:46 ON 27 MAR 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 10:44:46 ON 27 MAR 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'USPATFULL' ENTERED AT 10:44:46 ON 27 MAR 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

\*\*\* YOU HAVE NEW MAIL \*\*\*

=> s nucleotide? and thiol? (4a) base?  
L1 353 NUCLEOTIDE? AND THIOL? (4A) BASE?

=> s l1 and linker?  
L2 199 L1 AND LINKER?

=> s l2 and thiol (2a) base  
L3 28 L2 AND THIOL (2A) BASE

=> dup rem l3  
PROCESSING COMPLETED FOR L3  
L4 28 DUP REM L3 (0 DUPLICATES REMOVED)

=> d l4 bib abs 1-28

L4 ANSWER 1 OF 28 USPATFULL on STN  
AN 2004:7963 USPATFULL  
TI Method for sequential support-bound synthesis of conjugated oligomeric compounds  
IN Maier, Martin A., Carlsbad, CA, UNITED STATES  
Guzaev, Andrei P., Carlsbad, CA, UNITED STATES  
Manoharan, Muthiah, Carlsbad, CA, UNITED STATES  
PI US 2004006203 A1 20040108  
AI US 2002-176419 A1 20020620 (10)  
DT Utility  
FS APPLICATION  
LREP WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE - 46TH FLOOR, PHILADELPHIA, PA, 19103  
CLMN Number of Claims: 45  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Page(s)  
LN CNT 2821

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A sequential support-bound synthesis method is disclosed for preparing a conjugated oligomeric compound, preferably a PNA-peptide conjugate or an oligonucleotide-peptide conjugate, using a bridging molecule having at



09567863

least two N-protecting amino groups. A conjugated oligomeric compound for therapeutic or prophylactic delivery is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 28 USPATFULL on STN  
AN 2003:319267 USPATFULL  
TI Chimeric immunomodulatory compounds and methods of using the same - III  
IN Fearon, Karen L., Lafayette, CA, UNITED STATES  
Dina, Dino, Oakland, CA, UNITED STATES  
Tuck, Stephen F., Oakland, CA, UNITED STATES  
PI US 2003225016 A1 20031204  
AI US 2002-328578 A1 20021223 (10)  
RLI Continuation-in-part of Ser. No. US 2002-176883, filed on 21 Jun 2002,  
PENDING Continuation-in-part of Ser. No. US 2002-177826, filed on 21 Jun  
2002, PENDING  
PRAI US 2001-299883P 20010621 (60)  
US 2002-375253P 20020423 (60)  
US 2001-299883P 20010621 (60)  
US 2002-375253P 20020423 (60)  
DT Utility  
FS APPLICATION  
LREP Randolph T. Apple, Morrison & Foerster LLP, 755 Page Mill Road, Palo  
Alto, CA, 94304-1018  
CLMN Number of Claims: 33  
ECL Exemplary Claim: 1  
DRWN 19 Drawing Page(s)  
LN.CNT 7262

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides immunomodulatory compounds and methods for  
immunomodulation of individuals using the immunomodulatory compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 28 USPATFULL on STN  
AN 2003:283122 USPATFULL  
TI Chimeric immunomodulatory compounds and methods of using the same - II  
IN Fearon, Karen L., Lafayette, CA, UNITED STATES  
Dina, Dino, Oakland, CA, UNITED STATES  
Tuck, Stephen F., Oakland, CA, UNITED STATES  
PI US 2003199466 A1 20031023  
AI US 2002-177826 A1 20020621 (10)  
PRAI US 2001-299883P 20010621 (60)  
US 2002-375253P 20020423 (60)  
DT Utility  
FS APPLICATION  
LREP Randolph T. Apple, Morrison & Foerster LLP, 755 Page Mill Road, Palo  
Alto, CA, 94304-1018  
CLMN Number of Claims: 33  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Page(s)  
LN.CNT 7228

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides immunomodulatory compounds and methods for  
immunomodulation of individuals using the immunomodulatory compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 28 USPATFULL on STN  
AN 2003:250945 USPATFULL  
TI Chimeric immunomodulatory compounds and methods of using the same - I  
IN Fearon, Karen L., Lafayette, CA, UNITED STATES



09567863

Dina, Dino, Oakland, CA, UNITED STATES  
Tuck, Stephen F., Oakland, CA, UNITED STATES  
PI US 2003175731 A1 20030918  
AI US 2002-176883 A1 20020621 (10)  
PRAI US 2001-299883P 20010621 (60)  
US 2002-375253P 20020423 (60)  
DT Utility  
FS APPLICATION  
LREP Randolph T. Apple, Morrison & Foerster LLP, 755 Page Mill Road, Palo  
Alto, CA, 94304-1018  
CLMN Number of Claims: 30  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Page(s)  
LN.CNT 7092  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention provides immunomodulatory compounds and methods for  
immunomodulation of individuals using the immunomodulatory compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 28 USPATFULL on STN  
AN 2003:237692 USPATFULL  
TI Methods and reagents for introducing a sulfhydryl group into the  
5'-terminus of RNA  
IN Zhang, Biliang, Shrewsbury, MA, UNITED STATES  
Cui, Zhiyong, Worcester, MA, UNITED STATES  
Zhang, Lei, Agawam, MA, UNITED STATES  
PI US 2003165849 A1 20030904  
AI US 2001-996139 A1 20011127 (9)  
PRAI US 2000-253564P 20001128 (60)  
DT Utility  
FS APPLICATION  
LREP NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER WEST, 155 SEAPORT  
BOULEVARD, BOSTON, MA, 02210-2604  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1  
DRWN 14 Drawing Page(s)  
LN.CNT 1544

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for synthesizing RNA molecules whose 5'-terminus comprises a  
thiol group are disclosed. The present invention discloses the formation  
of 5'-HS-PEG-GMP-RNA and 5'-GMP-S-RNA which upon alkaline phosphatase  
treatment, independently lead to a 5'-HS-RNA molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 28 USPATFULL on STN  
AN 2003:200449 USPATFULL  
TI Selective cellular targeting: multifunctional delivery vehicles,  
multifunctional prodrugs, use as antineoplastic drugs  
IN Glazier, Arnold, Newton, MA, UNITED STATES  
PA Drug Innovation & Design, Inc. (U.S. corporation)  
PI US 2003138432 A1 20030724  
AI US 2000-738625 A1 20001215 (9)  
RLI Continuation of Ser. No. US 2000-712465, filed on 15 Nov 2000, ABANDONED  
PRAI US 1999-165485P 19991115 (60)  
US 2000-239478P 20001011 (60)  
US 2000-241939P 20001010 (60)  
DT Utility  
FS APPLICATION  
LREP N. Scott Pierce, Esq., HAMILTON, BROOK, SMITH & REYNOLDS, P.C., Two  
Militia Drive, Lexington, MA, 02421-4799



**Search Notes**

Application No.

10/070,728

Examiner

Jezia Riley

Applicant(s)

SPERLING ET AL.

Art Unit

1637

**SEARCHED**

Class	Subclass	Date	Examiner
435	6		
536	23.1 24.3		
536	25.3 26.6	3/27/2004	JR

**INTERFERENCE SEARCHED**

Class	Subclass	Date	Examiner

**SEARCH NOTES  
(INCLUDING SEARCH STRATEGY)**

	DATE	EXMR
STN search enclosed	3/27/2004	JR



# Index of Claims



Application No.

10/070,728

Examiner

Jezia Riley

Applicant(s)

SPERLING ET AL.

Art Unit

1637

✓	Rejected
=	Allowed

-	(Through numeral) Cancelled
+	Restricted

N	Non-Elected
I	Interference

A	Appeal
O	Objected

Claim		Date											
Final	Original	3/27/04											
	1	✓											
	2	✓											
	3	✓											
	4	✓											
	5	✓											
	6	✓											
	7	✓											
	8	✓											
	9	✓											
	10	✓											
	11	✓											
	12	✓											
	13	✓											
	14	✓											
	15	✓											
	16	✓											
	17	✓											
	18	✓											
	19	✓											
	20	✓											
	21	✓											
	22	✓											
	23	✓											
	24												
	25												
	26												
	27												
	28												
	29												
	30												
	31												
	32												
	33												
	34												
	35												
	36												
	37												
	38												
	39												
	40												
	41												
	42												
	43												
	44												
	45												
	46												
	47												
	48												
	49												
	50												

Claim		Date											
Final	Original												
	51												
	52												
	53												
	54												
	55												
	56												
	57												
	58												
	59												
	60												
	61												
	62												
	63												
	64												
	65												
	66												
	67												
	68												
	69												
	70												
	71												
	72												
	73												
	74												
	75												
	76												
	77												
	78												
	79												
	80												
	81												
	82												
	83												
	84												
	85												
	86												
	87												
	88												
	89												
	90												
	91												
	92												
	93												
	94												
	95												
	96												
	97												
	98												
	99												
	100												

Claim		Date											
Final	Original												
	101												
	102												
	103												
	104												
	105												
	106												
	107												
	108												
	109												
	110												
	111												
	112												
	113												
	114												
	115												
	116												
	117												
	118												
	119												
	120												
	121												
	122												
	123												
	124												
	125												
	126												
	127												
	128												
	129												
	130												
	131												
	132												
	133												
	134												
	135												
	136												
	137												
	138												
	139												
	140												
	141												
	142												
	143												
	144												
	145												
	146												
	147												
	148												
	149												
	150												